Overview

Clinical Study of SM3321 With Solid Tumors

Status:
Recruiting
Trial end date:
2025-10-14
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the Safety and Tolerability of SM3321 in patients with locally advanced or metastatic solid tumors
Phase:
Phase 1
Details
Lead Sponsor:
Beijing StarMab Biomed Technology Ltd